Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients.

Academic Article

Abstract

  • The morning blood pressure surge (MBPS) has been shown to be an independent predictor of cardiovascular events. There is insufficient evidence on the effect of nebivolol, a vasodilating β1-receptor blocker, on the MBPS when given in the morning or the evening. This is a prospective, randomized, double-blind, crossover study designed to test morning vs. evening dosing of nebivolol in nondiabetic, hypertensive patients. Patients received nebivolol 5 mg/day (force-titrated to 10 mg/day after 1 week) in the morning or evening and corresponding placebos. Patients underwent ambulatory BP monitoring at baseline and after each treatment phase. Forty-two patients were randomized, of whom 38 completed both study periods. Both morning and evening dosed nebivolol significantly lowered daytime, nighttime, and 24-hour BP after 3 weeks of treatment. Evening (but not morning) dosing significantly reduced prewaking systolic BP from baseline (8.64 ± 26.46 mm Hg, P = .048). Nebivolol given in the morning or the evening significantly reduces 24-hour BP parameters. Evening dosed nebivolol may confer some advantage over morning dosing in reducing prewaking systolic BP.
  • Keywords

  • Adult, Aged, Antihypertensive Agents, Benzopyrans, Blood Pressure Monitoring, Ambulatory, Cross-Over Studies, Double-Blind Method, Drug Chronotherapy, Ethanolamines, Female, Humans, Hypertension, Male, Middle Aged, Nebivolol, Prospective Studies, Treatment Outcome, Young Adult
  • Digital Object Identifier (doi)

    Author List

  • Acelajado MC; Pisoni R; Dudenbostel T; Oparil S; Calhoun DA; Glasser SP
  • Start Page

  • 66
  • End Page

  • 72
  • Volume

  • 6
  • Issue

  • 1